Immunotherapy for renal cell cancer.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  QJM : monthly journal of the Association of Physicians

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/QJMED/91.9.597PMID 10024913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

  1996cited by this paper
• Comprehensive Textbook of Genitourinary Oncology

  1996cited by this paper
• Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette‐Guèrin: Five‐year results of a prospective randomized study

  1996cited by this paper
• Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.

  1995cited by this paper
• Active specific immunotherapy with an autologous virus-modified tumour cell vaccine in human renal cell carcinoma (RCC)

  1995cited by this paper
• Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.

  1995cited by this paper
• Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

  1995cited by this paper
• Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma

  1995cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.

  1995cited by this paper
• Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

  1994cited by this paper
• Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha.

  1994cited by this paper
• Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients.

  1994cited by this paper
• Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden.

  1994cited by this paper
• Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.

  1993cited by this paper
• Immunotherapy for metastatic renal cell carcinoma.

  1993cited by this paper
• Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

  1993cited by this paper
• Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

  1993cited by this paper
• Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

  1993cited by this paper
• Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

  1993cited by this paper
• Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.

  1992cited by this paper
• Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.

  1992cited by this paper
• Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.

  1992cited by this paper
• Mechanism of interferon action: autoregulation of RNA-dependent P1/eIF-2 alpha protein kinase (PKR) expression in transfected mammalian cells.

  1992cited by this paper
• Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice.

  1992cited by this paper
• Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

  1991cited by this paper
• Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.

  1990cited by this paper
• Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

  1988cited by this paper
• In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

  1988cited by this paper
• A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

  1986cited by this paper
• Interaction of recombinant interferons with recombinant interleukin‐2: Differential effects on natural killer cell activity and interleukin‐2‐activated killer cells

  1986cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2

  1985cited by this paper
• Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.

  1985cited by this paper
• Management of Metastatic Disease of Bone

  1984cited by this paper
• Renal cell carcinoma: antitumor effects of leukocyte interferon.

  1983cited by this paper
• Spontaneous regression of metastatic renal cell carcinoma.

  1982cited by this paper
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

  1982cited by this paper
• Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

  1981cited by this paper
• In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

  1980cited by this paper
• The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma.

  1977cited by this paper
• Idiopathic regression of metastases from renal cell carcinoma.

  1977cited by this paper
• Hormone-induced and spontaneous regression of metastatic renal cancer

  1974cited by this paper
• Hormone-Dependent Tumours of the Kidney

  1963cited by this paper

• Prognostic value of the neutrophil‑to‑lymphocyte ratio in renal cell carcinoma: A systematic review and meta‑analysis

  2025cites this paper
• Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma

  2021cites this paper
• MMP9 and IGFBP1 Regulate Tumor Immune and Drive Tumor Progression in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma

  2020cites this paper
• The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma

  2019cites this paper
• Bayesian Designs for Early Phase Clinical Trials with Novel Target Agents

  2018cites this paper
• G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas

  2018cites this paper
• HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape

  2017cites this paper
• Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models

  2017cites this paper
• Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

  2016cites this paper
• Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma

  2016cites this paper
• Anti‐PD‐L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma

  2016cites this paper
• Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma

  2016cites this paper
• Association between Perioperative Blood Transfusion and Oncologic Outcomes after Curative Surgery for Renal Cell Carcinoma

  2016cites this paper
• Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma

  2015cites this paper
• Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

  2015cites this paper
• Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor

  2014cites this paper
• Stratification of clear cell renal cell carcinoma by signaling pathway analysis

  2014cites this paper
• PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

  2014cites this paper
• Evaluation of everolimus in renal cell cancer

  2013cites this paper
• Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4

  2013cites this paper
• Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

  2013cites this paper
• IFNα2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients - A preliminary study

  2012cites this paper
• Induction of apoptosis and cell cycle arrest in renal carcinoma cells by phenethyl isothiocyanate and the mechanisms involved

  2011cites this paper
• Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway.

  2011cites this paper
• Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after

  2011cites this paper
• A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR

  2011cites this paper
• Immunotherapy for Renal Cell Carcinoma

  2010influential citation
• Anti-Tumor Activity of Genetically Redirected T Cells Against Orthotopic Kidney Cancer in Mice~!2010-01-06~!2010-03-24~!2010-05-13~!

  2010cites this paper
• Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma

  2010cites this paper
• Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases

  2010cites this paper
• Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation

  2010cites this paper
• TARGETED THERAPY FOR METASTATIC RENAL CELL CANCER

  2010cites this paper
• Antitumor Reactivity In Vitro Sorafenib Differentially Affect NK Cell The Kinase Inhibitors Sunitinib and

  2009cites this paper
• Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

  2009cites this paper
• Current Role of Immunotherapy for Advanced Renal Cell Carcinoma in the Era of Targeted Therapy

  2009cites this paper
• The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro1

  2009cites this paper
• T Cell–Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective

  2009influential citation
• Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

  2009cites this paper
• Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study.

  2009influential citation
• MECHANISM OF MYELOID-DERIVED SUPPRESSOR CELL ACCUMULATION IN CANCER AND SUSCEPTIBILITY TO REVERSAL BY SUNITINIB

  2009cites this paper
• Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma

  2009cites this paper
• 5T4 as a target for immunotherapy in renal cell carcinoma

  2009cites this paper
• Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

  2009cites this paper
• Current and Future Treatment Options for Metastatic Renal Cell Carcinoma

  2009cites this paper
• An investigation of the role of the systemic and local inflammatory response in patients undergoing resection for renal cell carcinoma

  2008cites this paper
• Interleukin 21: combination strategies for cancer therapy

  2008cites this paper
• IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

  2008cites this paper
• Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma

  2008cites this paper
• Immunotherapy for renal cell cancer in the era of targeted therapy

  2008cites this paper
• Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

  2008cites this paper
• Chemokine Receptors Expression and Migration Potential of Tumor-infiltrating and Peripheral-expanded Vγ9Vδ2 T Cells From Renal Cell Carcinoma Patients

  2008cites this paper
• Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer

  2008cites this paper
• C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients

  2008cites this paper
• Renal cell carcinoma: changes in natural history and treatment of metastatic disease

  2007cites this paper
• Renal cell carcinoma

  2007cites this paper
• Recent developments in renal cell cancer immunotherapy

  2007cites this paper
• Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer

  2007cites this paper
• Renal cell cancer: is immunotherapy dead?

  2007influential citation
• Top-line summary aDVaNCED rENaL CELL CarCiNOma Hitting the target with novel systemic therapies

  2007cites this paper
• Vaccinotherapy in renal cell carcinoma

  2007cites this paper
• Update on anti-CTLA-4 antibodies in clinical trials

  2007cites this paper
• Valor pronóstico del tamaño nucleolar en el carcinoma de células renales - estudio mediante morfometría ultraestructural

  2007influential citation
• Cytokine therapy: a standard of care for metastatic renal cell carcinoma?

  2005cites this paper
• Renal Cell Carcinoma: Diagnosis and Treatment, 1994–2003

  2005cites this paper
• Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.

  2004cites this paper
• Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.

  2001cites this paper
• Renal cell carcinoma

  2001cites this paper
• Active Specific Immunotherapy of Renal Cell Carcinoma: Cellular and Humoral Immune Responses

  1997cites this paper
• Renal-cell Carcinoma

  1976cites this paper